Medscape
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for brentuximab vedotin (Adcetris; Seagen, Inc., a Pfizer subsidiary), in combination with lenalidomide and rituximab, for adults with large B-cell lymphoma that recurs or fails to respond to at least two prior lines of therapy…
Read More
FDA Approves BV+R2 Combo for R/R LBCL
Diego Latson
08:23
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for brentuximab vedotin (Adcetris; Seagen, Inc., a Pfizer subsidiary), in combination with lenalidomide and rituximab, for adults with large B-cell lymphoma that recurs or fails to respond to at least two prior lines of therapy…
